



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Services
Prior Authorization Criteria
Vowst® (fecal microbiota spores, live-brpk)
Effective 9/20/2023

Prior Authorization Request Form

Vowst (fecal microbiota spores, live-brpk) is indicated to prevent the recurrence of *Clostridioides difficile* infection (CDI) in individuals 18 years of age and older following an antibacterial treatment for recurrent CDI (rCDI).

Limitation of Use: VOWST is not indicated for treatment of CDI.

CRITERIA FOR APPROVAL:

1. The patient has a confirmed diagnosis of recurrent *Clostridioides difficile* infection with a total of ≥ 3 episodes of CDI within 12 months; **AND**
2. The CDI episodes were defined as diarrhea (≥ 3 unformed stools per day for at least 2 consecutive days) and a positive *C. difficile* stool sample using a toxin assay; **AND**
3. The patient is within the age range as recommended by the FDA label; **AND**
4. For prior CDIs patient has been trialed on the following regimen:

Primary episode of CDI: Completed one or more round(s) of standard-of-care antibiotic therapy (e.g. metronidazole, vancomycin or fidaxomicin); **AND**

For first or subsequent relapse: Completed a round of pulsed-dosed fidaxomicin (200 mg orally twice daily for 5 days, followed by once every other day for 20 days).

Requests for an additional course of Vowst therapy may only be authorized if the following criteria has been met:

1. The patient must have at least two relapses with documentation of CDI (as defined above) following Vowst treatment; **AND**
2. The patient must have completed an additional round on pulsed dosed fidaxomicin and trialed on Zinplava (either for the same episode or separate episodes).



**STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES**



Requests for additional therapy after treatment with a second course of Vowst will not be authorized within the subsequent year. Alternative treatment options should be considered.

References:

1. Lexicomp monograph for Vowst (9/2023)
2. Vowst package insert
3. UpToDate Clinical monograph: Fecal microbiota transplantation for treatment of *Clostridioides difficile* infection (9/2023)
4. UpToDate Clinical monograph: *Clostridioides difficile* infection in adults: Treatment and prevention (9/2023)